Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Porter J.M., Gregory L., Moneta G.L..
Classification and grading of chronic venous disease. A consensus statement.
J Vasc Surg., 21 (1995), pp. 635-645
[2.]
Rosendaal F.R..
Thrombosis in the young: epidemiology and risk factors, a focus in venous thrombosis.
Thromb Hemost, 78 (1997), pp. 1-6
[3.]
Rutherford R.B., Clagett G.P., Cranley J.J., O'Donnell T.F., Raju S., Zierler R.E., et al.
Reporting standards in venous disease.
J Vasc Surg., 8 (1988), pp. 172-181
[4.]
Egeberg O..
Inherited antitrombin deficiency causing thrombophilia.
Thromb Diath Hemorrh., 13 (1965), pp. 516-530
[5.]
Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C..
Deficiency of protein C in congenital thrombotic disease.
J Clin Invest, 68 (1981), pp. 1370-1373
[6.]
Schwarz H.P., Fischer M., Hopmeier P., Batard M.A., Griffin J.H..
Plasma protein S deficiency in familial thrombotic disease.
Blood, 64 (1984), pp. 1297-1300
[7.]
Porter J.M., Moneta J.L..
Reporting standards in venous disease: an update.
J Vasc Surg., 21 (1995), pp. 635-645
[8.]
Homans J..
Thrombosis of the leg veins due to prolonged sitting.
N Engl J Med., 250 (1954), pp. 148-149
[9.]
Savesvaan R..
Sudden natural deaths associated with commercial air travel.
Med Sci Law, 26 (1986), pp. 35-38
[10.]
Lapostolle F., Surget V., Borron S.W., Desmaizieres M., Sordelet D., Lapandry C., et al.
Severe pulmonary embolism associated with air travel.
N Engl Med., 345 (2001), pp. 779-783
[11.]
Kraaijenhaghen RA, Haverkamp D, Koopman MM, Prandoni P. Piovella F, Büller HR. Travel and risk of venous thrombosis. Lancet 200; 356: 1492-3.
[12.]
Ferrari E., Cevallier T., Chapelier A., Baudouy M..
Travel as a study.
Chest, 115 (1999), pp. 440-444
[13.]
Cohen S.H., Ehrlich G.E., Kaufman M.S., Cope C..
Thrombophlebitis following knee surgery.
J Bone Surg., 55 (1973), pp. 106-111
[14.]
Hull R.D., Raskob G.E..
Prophylaxis of venous thromboembolic disease following hip and knee surgery.
J Bone Surg., 68 (1986), pp. 146-150
[15.]
Mayo M., Halil T., Browse N.L..
The incidence of deep vein thrombosis after prostatectomy.
Br J Urol, 43 (1971), pp. 738-742
[16.]
Geerts W.H., Code K.I., Jay R.M., Chen E., Szalai J.P..
A prospective study of venous thromboembolism after mayor trauma.
N Engl J Med., 331 (1944), pp. 1601-1606
[17.]
Trousseau A..
Phegmasia Alba Dolens.
Clinique Médicale de l'Hôtel-Dieu de Paris, JB Ballière et fils, (1865),
[18.]
Bick R.L..
Coagulation abnormalities in malignancy: a review.
Sem Thromb Hemost, 18 (1992), pp. 353-369
[19.]
Meier C.R., Jic H..
Tamoxifen and risk of idiopathic venous thromboembolism.
Br J Clin Pharmacol., 45 (1998), pp. 608-612
[20.]
Weijl N.I., Rutten M.F., Zwinderman A.H., Keizer H.J., Nooy M.A., Rosendaal F.R., et al.
Thromboembolic events during chemoteraphy for germ cell cancer: a cohort study and review of the literature.
J Clin Oncol., 18 (2000), pp. 2169-2178
[21.]
Nordstrom M., Lindblad B., Anderson H., Bergqvist D., Kjellströ T..
Deep venous thrombosis and occult malignancy: an epidemiological study.
BMJ, 308 (1994), pp. 891-894
[22.]
World Health Organization.
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet, 346 (1995), pp. 1575-1582
[23.]
Gertsman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Laundin F.E..
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
Am J Epidemiol., 133 (1991), pp. 32-37
[24.]
World Health Organization.
Effect of different progestagens in low estrogen oral contracetives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascuar Disease and Steroid Hormone Contraception.
Lancet, 346 (1995), pp. 1582-1588
[25.]
Kemmeren J.M., Algra A., Grobee D.E..
Third generation oral contraceptives with differing progression components.
Lancet, 346 (1995), pp. 1589-1593
[26.]
Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S..
Risk of venous thromboembolism in users of hormone replacement teraphy.
Lancet, 348 (1996), pp. 977-980
[27.]
Grady D., Furberg C..
Venous thromboembolic events associated with hormone replacement therapy.
JAMA, 278 (1997), pp. 477
[28.]
McColl M.D., Ramsay J.E., Tait R.C., Walker I.D., McCall F., Conkie J.A., et al.
Risk factors for pregnancy associated venous thrombosis.
Thromb Haemost., 78 (1997), pp. 1183-1188
[29.]
Kierkegaard A..
Incidence and diagnosis of deep vein thrombosis associated with pregnancy.
Acta Obstet Gynecol Scand, 62 (1983), pp. 239-243
[30.]
Tait R.C., Walker I.D., Perry D.J., Islam S.I., Daly M.E., McCall F., et al.
Prevalence of antithrombin deficiency in the healthy population.
Br J Haematol., 87 (1994), pp. 106-112
[31.]
Tait R.C., Walker I.D., Reitsma P.H., Islam S.I., McCall F., Poort S.R., et al.
Prevalence of protein C deficiency in the healthy population.
Thromb Haemost., 73 (1995), pp. 87-93
[32.]
Dahlbäck B., Carlsson M., Svensson P.J..
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C.
Proc Natl Acad Sci U S A, 90 (1993), pp. 1004-1008
[33.]
Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., et al.
Mutation in blood coagulation factor V associated with resistance to activated protein C.
Nature, 369 (1994), pp. 64-67
[34.]
Rees D.C., Cox M., Clegg J.B..
World distribution of factor V Leiden.
Lancet, 346 (1995), pp. 1133-1134
[35.]
Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H..
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).
Blood, 85 (1995), pp. 1504-1508
[36.]
Koster T., Rosendaal F.R., De Ronde H., Briét E., Vandenbroucke J.P., Bertina R.M..
Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.
Lancet, 342 (1993), pp. 1503-1506
[37.]
Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M..
A common genetic variation in the 3'untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
Blood, 88 (1996), pp. 3698-3703
[38.]
Bertina R.M..
Factor V Leiden and other coagulation factor mutations affecting thrombotic risk.
Clin Chem., 43 (1997), pp. 1678-1683
[39.]
Jick H., Slone D., Westerholm B., Inman W.H., Vessey M.P., Shapiro S., et al.
Venous thromboembolic disease and ABO blood type.
Lancet, 1 (1969), pp. 539-542
[40.]
Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al.
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.
Nat Genet, 10 (1995), pp. 111-113
[41.]
Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., et al.
The natural history of homocystinuria due to cystathionine beta-syntetase deficiency.
Am J Hum Genet., 37 (1985), pp. 1-31
[42.]
Manoussakis M.N., Tzioufas A.G., Silis M.P., Pange P.J., Goudevenos J., Moutsopoulos H.M..
High prevalence of anticardiolipin and other autoantibodies in a healthy elderly population.
Clin Exp Inmunol., 69 (1987), pp. 557-565
[43.]
Insko E.K., Haskal Z.J..
Antiphospolipid syndrome: patterns of life-threatening and severe recurrent vascular complications.
Radiology, 202 (1997), pp. 319-326
[44.]
Ahn S.S., Kalunian K., Rosove M., Moore W.S..
Postoperative thrombotic complications in patients with the lupus anticoagulant: increased risk after vascular procedures.
J Vasc Surg., 7 (1988), pp. 745-756
[45.]
Koster T., Blann A.D., Briét E., Vandenbroucke J.P., Rosendaal F.R..
Role of clotting factor VIII in effect of von Willebrand factor on ocurrence of deep-vein thrombosis.
Lancet, 345 (1995), pp. 152-155
[46.]
Colleen D., Juhan-Vaghe I..
Fibrinolisis and atheroesclerosis.
Sem Thromb Hemost, 14 (1988), pp. 180-183
[47.]
Hasegawa D.H., Tyler B.J., Edson J.R..
Thrombotic disease in three families with inherited plasminogen deficiency.
Blood, 60 (1982), pp. 213-217
[48.]
Nilsson I.M., Tengborn L.A..
A family with thrombosis associated with high level of tissue plasminogen activator inhibitor.
Haemostasis, 14 (1984), pp. 24-27
[49.]
Anderson F.A. Jr., Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., et al.
A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.
Arch Intern Med., 151 (1991), pp. 933-938
[50.]
Vandenbroucke J.P., Koster T., Briét E., Reitsma P.H., Bertina R.M., Rosendaal F.R..
Increased risk of venous thrombosis in oral contraceptives users who are carriers of factor V Leiden mutation.
Lancet, 344 (1994), pp. 1453-1457
Copyright © 2003. SEACV
